Pulmonary recovery from COVID-19 in patients with metabolic diseases: a longitudinal prospective cohort study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 02 2023
14 02 2023
Historique:
received:
28
03
2022
accepted:
08
02
2023
entrez:
14
2
2023
pubmed:
15
2
2023
medline:
17
2
2023
Statut:
epublish
Résumé
The severity of coronavirus disease 2019 (COVID-19) is related to the presence of comorbidities including metabolic diseases. We herein present data from the longitudinal prospective CovILD trial, and investigate the recovery from COVID-19 in individuals with dysglycemia and dyslipidemia. A total of 145 COVID-19 patients were prospectively followed and a comprehensive clinical, laboratory and imaging assessment was performed at 60, 100, 180, and 360 days after the onset of COVID-19. The severity of acute COVID-19 and outcome at early post-acute follow-up were significantly related to the presence of dysglycemia and dyslipidemia. Still, at long-term follow-up, metabolic disorders were not associated with an adverse pulmonary outcome, as reflected by a good recovery of structural lung abnormalities in both, patients with and without metabolic diseases. To conclude, dyslipidemia and dysglycemia are associated with a more severe course of acute COVID-19 as well as delayed early recovery but do not impair long-term pulmonary recovery.
Identifiants
pubmed: 36788324
doi: 10.1038/s41598-023-29654-1
pii: 10.1038/s41598-023-29654-1
pmc: PMC9926446
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2599Informations de copyright
© 2023. The Author(s).
Références
Diabetes Care. 2020 Oct;43(10):2345-2348
pubmed: 32788285
Diabetol Metab Syndr. 2020 Aug 31;12:75
pubmed: 32874207
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):382-388
pubmed: 30641729
Nat Rev Endocrinol. 2021 Jan;17(1):11-30
pubmed: 33188364
Crit Care. 2011 Apr 20;15(2):221
pubmed: 21586104
Clin Chem Lab Med. 2021 Apr 09;59(8):1453-1462
pubmed: 33837679
J Clin Lipidol. 2021 Sep-Oct;15(5):724-731
pubmed: 34470719
J Diabetes Sci Technol. 2020 Jul;14(4):813-821
pubmed: 32389027
Front Cardiovasc Med. 2022 Mar 24;9:862999
pubmed: 35402531
Diabetes Care. 2021 Feb;44(2):578-585
pubmed: 33323475
Crit Care. 2020 Jul 9;24(1):406
pubmed: 32646467
Diabetes Care. 2021 Dec;44(12):2645-2655
pubmed: 34625431
Cell Metab. 2020 Dec 1;32(6):1041-1051.e6
pubmed: 33207244
J Clin Invest. 2008 Jan;118(1):364-75
pubmed: 18064300
Front Microbiol. 2021 Nov 11;12:761887
pubmed: 34858373
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1463-1465
pubmed: 32771919
Endocrine. 2022 Aug;77(2):392-400
pubmed: 35676466
Front Endocrinol (Lausanne). 2020 Nov 13;11:596898
pubmed: 33281748
Obes Rev. 2009 May;10(3):269-79
pubmed: 19389061
J Endocrinol Invest. 2020 Jun;43(6):867-869
pubmed: 32222956
Viruses. 2021 Nov 30;13(12):
pubmed: 34960670
Crit Care. 2021 Aug 19;25(1):300
pubmed: 34412661
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Acta Biomed. 2020 Mar 19;91(1):161-164
pubmed: 32191676
Clin Chim Acta. 2007 May 1;380(1-2):24-30
pubmed: 17343838
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Crit Care. 2016 Sep 27;20(1):301
pubmed: 27677709
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2128-2130.e2
pubmed: 32334082
Metabolism. 2020 Jun;107:154216
pubmed: 32220612
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
J Lipid Atheroscler. 2020 Sep;9(3):435-448
pubmed: 33024735
Annu Rev Med. 2022 Jan 27;73:129-147
pubmed: 34379444
Elife. 2022 Feb 08;11:
pubmed: 35131031
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102307
pubmed: 34731820
Diabetes Obes Metab. 2020 Oct;22(10):1897-1906
pubmed: 32469464
bioRxiv. 2021 Dec 30;:
pubmed: 35018379
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1279-1286
pubmed: 30982158
J Infect. 2021 Jun;82(6):276-316
pubmed: 33684401
Diabetes Care. 2020 Jul;43(7):1408-1415
pubmed: 32430456
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
Nat Rev Immunol. 2015 Feb;15(2):104-16
pubmed: 25614320
Cell Metab. 2021 Nov 2;33(11):2174-2188.e5
pubmed: 34599884
Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):908-15
pubmed: 17272752
Nature. 1998 Oct 22;395(6704):763-70
pubmed: 9796811
J Clin Exp Hepatol. 2021 Feb 08;:
pubmed: 33584063
Front Cell Infect Microbiol. 2021 Jun 23;11:678482
pubmed: 34282405
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32706339
Physiol Rep. 2021 Apr;9(7):e14843
pubmed: 33904656
Diabetes Metab. 2021 Nov;47(6):101268
pubmed: 34333093
Wien Klin Wochenschr. 2021 Dec;133(23-24):1237-1247
pubmed: 34661740
Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792
pubmed: 32687793
Nature. 2017 Feb 8;542(7640):177-185
pubmed: 28179656
Arch Virol. 2018 Nov;163(11):3119-3124
pubmed: 30051343
Diabetes Res Clin Pract. 2020 Oct;168:108374
pubmed: 32805345
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
Diabetes Obes Metab. 2021 Mar;23(3):870-874
pubmed: 33245182
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
Cell Metab. 2022 Jan 4;34(1):1-2
pubmed: 34895500
Am J Med Sci. 2016 Feb;351(2):201-11
pubmed: 26897277
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Diabetes Care. 2020 Aug;43(8):e83-e85
pubmed: 32503837
Mayo Clin Proc. 2017 May;92(5):762-773
pubmed: 28302323
Microbes Infect. 2007 Jan;9(1):96-102
pubmed: 17194611
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Respir Res. 2020 Oct 21;21(1):276
pubmed: 33087116
Lancet Diabetes Endocrinol. 2021 Jun;9(6):328-329
pubmed: 33838106
Cell Metab. 2021 Aug 3;33(8):1565-1576.e5
pubmed: 34081912
Am J Respir Crit Care Med. 2022 Feb 15;205(4):388-396
pubmed: 34715007
J Clin Invest. 2011 Jun;121(6):2111-7
pubmed: 21633179
Clin Chim Acta. 2021 Jun;517:66-73
pubmed: 33639119
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303539